Skip to Main Content

After Pfizer (PFE) and BioNTech (BNTX) announced a plan to widen access to Covid-19 vaccines by striking a production deal with a South African company, the effort was quickly panned by patient advocates who argued the arrangement does not go far enough.

In a ballyhooed announcement, the drug makers said they contracted with The Biovac Institute, a vaccine maker backed in part by the South African government, to assemble the final stages of their Covid-19 vaccine, a process known in the pharmaceutical industry as “fill-and-finish.” From there, more than 100 million finished doses will be supplied exclusively to all 55 African Union countries annually.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment